within Pharmacolibrary.Drugs.S_SensoryOrgans.S03C_CorticosteroidsAndAntiinfectivesInCombination.S03CA02_PrednisoloneAndAntiinfectives;

model PrednisoloneAndAntiinfectives
  extends Pharmacolibrary.Drugs.ATC.S.S03CA02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S03CA02</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Prednisolone and antiinfectives (ATC code S03CA02) is a combination used primarily in ophthalmic preparations for the treatment of inflammatory eye conditions with suspected or proven bacterial infection. Prednisolone is a corticosteroid that reduces inflammation, while the antiinfective component treats or prevents infection. These combination eye drops or ointments are approved for short-term use in managing conditions like conjunctivitis or keratitis.</p><h4>Pharmacokinetics</h4><p>There are no published pharmacokinetic models or parameters specifically for the ophthalmic combination of prednisolone and antiinfectives (ATC S03CA02). Systemic exposure from ophthalmic administration is minimal and pharmacokinetic parameters are not well established. The estimates below are based on general knowledge of ocular administration and the systemic PK of prednisolone after ocular routes.</p><h4>References</h4><ol><li><p>Lee, H, et al., &amp; Kim, SW (2023). Corticosteroid-Antibiotic Interactions in Bacteria that Cause Corneal Infection. <i>Translational vision science &amp; technology</i> 12(5) 16–None. DOI:<a href=&quot;https://doi.org/10.1167/tvst.12.5.16&quot;>10.1167/tvst.12.5.16</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37184498/&quot;>https://pubmed.ncbi.nlm.nih.gov/37184498</a></p></li><li><p>Moksha, L, et al., &amp; Velpandian, T (2021). Pharmacoproteomic analysis of topical dapsone and prednisolone interventions in the aqueous humor of anterior uveitis. <i>Experimental eye research</i> 206 108534–None. DOI:<a href=&quot;https://doi.org/10.1016/j.exer.2021.108534&quot;>10.1016/j.exer.2021.108534</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33722510/&quot;>https://pubmed.ncbi.nlm.nih.gov/33722510</a></p></li><li><p>Cheng, YH, et al., &amp; Liu, CJ (2021). Development of a dual delivery of levofloxacin and prednisolone acetate via PLGA nanoparticles/ thermosensitive chitosan-based hydrogel for postoperative management: An in-vitro and ex-vivo study. <i>International journal of biological macromolecules</i> 180 365–374. DOI:<a href=&quot;https://doi.org/10.1016/j.ijbiomac.2021.03.017&quot;>10.1016/j.ijbiomac.2021.03.017</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33676980/&quot;>https://pubmed.ncbi.nlm.nih.gov/33676980</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end PrednisoloneAndAntiinfectives;
